EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

MiR-155 -targeted IcosL controls tumor rejection

Esmerina Tili, Hajime Otsu, Teresa L Commisso, Alexey Palamarchuk, Veronica Balatti, Jean-Jacques Michaille, Gerard James Nuovo, Carlo M Croce iD

Proceedings of the National Academy of Sciences · 2024

DOI: 10.1073/pnas.2408649121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Esmerina Tili und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Wexner Medical Center, College of Medicine, The Ohio State University, Columbus, OH 43210. Hauptthemen laut MEDLINE: MicroRNAs, Inducible T-Cell Co-Stimulator Ligand. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, CLL Global Research Foundation (CLLGRF), HHS | NIH | National Cancer Institute (NCI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Elevated levels of miR-155 in solid and liquid malignancies correlate with aggressiveness of the disease. In this manuscript, we show that miR-155 targets transcripts encoding IcosL, the ligand for Inducible T-cell costimulator (Icos), thus impairing the ability of T cells to recognize and eliminate malignant cells. We specifically found that overexpression of miR-155 in B cells of Eµ- miR-155 mice causes loss of IcosL expression as they progress toward malignancy. Similarly, in mice where miR-155 expression is controlled by a Cre-Tet-OFF system, miR-155 induction led to malignant infiltrates lacking IcosL expression. Conversely, turning miR-155 OFF led to tumor regression and emergence of infiltrates composed of IcosL-positive B cells and Icos-positive T cells forming immunological synapses. Therefore, we next engineered malignant cells to express IcosL, in order to determine whether IcosL expression would increase tumor infiltration by cytotoxic T cells and reduce tumor progression. Indeed, overexpressing an IcosL -encoding cDNA in MC38 murine colon cancer cells before injection into syngeneic C57BL6 mice reduced tumor size and increased intratumor CD8+ T cell infiltration, that formed synapses with IcosL-expressing MC38 cells. Our results underscore the fact that by targeting IcosL transcripts, miR-155 impairs the infiltration of tumors by cytotoxic T cells, as well as the importance of IcosL on enhancing the immune response against malignant cells. These findings should lead to the development of more effective anticancer treatments based on maintaining, increasing, or restoring IcosL expression by malignant cells, along with impairing miR-155 activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsInducible T-Cell Co-Stimulator LigandAnimalsMiceB-LymphocytesCell Line, TumorMice, Inbred C57BLHumansT-Lymphocytes, CytotoxicGene Expression Regulation, NeoplasticInducible T-Cell Co-Stimulator ProteinNeoplasms

Stichwörter der Autor:innen

immune rejectionimmune therapylymphomamicroRNA targetingsolid tumor

Substanzen

MicroRNAsInducible T-Cell Co-Stimulator LigandMirn155 microRNA, mouseIcosl protein, mouseInducible T-Cell Co-Stimulator Protein

Autor:innen und Institutionen

  • Department of Anesthesiology, Wexner Medical Center, College of Medicine, The Ohio State University, Columbus, OH 43210.
  • The Ohio State University, Comprehensive Cancer Center, Department of Cancer Biology and Genetics, Wexner Medical Center, Columbus, OH 43210.
  • GNOME, Inc., Powell, OH 43065.

ORCID-Profile: Carlo M Croce

Förderung

  • NCI NIH HHS
  • CLL Global Research Foundation (CLLGRF)
  • HHS | NIH | National Cancer Institute (NCI)

Zitieren

APA

Tili, E., Otsu, H., Commisso, T. L., Palamarchuk, A., Balatti, V., Michaille, J. J., Nuovo, G. J., & Croce, C. M. (2024). MiR-155 -targeted IcosL controls tumor rejection. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2408649121

Vancouver

Tili E, Otsu H, Commisso TL, Palamarchuk A, Balatti V, Michaille JJ, et al. MiR-155 -targeted IcosL controls tumor rejection. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2408649121

BibTeX
@article{Tili2024,
  author = {Tili, Esmerina and Otsu, Hajime and Commisso, Teresa L and Palamarchuk, Alexey and Balatti, Veronica and Michaille, Jean-Jacques and Nuovo, Gerard James and Croce, Carlo M},
  title = {MiR-155 -targeted IcosL controls tumor rejection},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2024},
  doi = {10.1073/pnas.2408649121}
}
Kostenlos starten →